Genetic variation screening of TNNT2 and MYH7 genes in a cohort of patients with hypertrophic and dilated cardiomyopathy


1 Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, Czech Republic
2 2nd Department of Internal Medicine - Clinical Department of Cardiology and Angiology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic

INTRODUCTION

Cardiomyopathies are generally defined as myocardial disorders in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to cause the observed myocardial abnormality. According to the morphological and functional phenotype the diagnosis of hypertrophic and dilated cardiomyopathy can be established. Hypertrophic cardiomyopathy (HCM) is an autosomal dominant cardiac disorder with a prevalence of 0.2% in the general population. More than 70% of HCM cases are familial. Hypertrophic cardiomyopathy represents one of the most frequent causes of sudden cardiac death in the young, especially in competitive athletes and a major cause of morbidity and mortality in the elderly. Dilated cardiomyopathy (DCM) is an inherited or acquired disease characterized by left ventricular dilatation and reduced systolic function. DCM represents the third most common cause of heart failure and the most frequent cause of heart transplantation. It accounts for approximately 3% of all sudden cardiac deaths in young athletes. Importantly, 30-50% of all cases are diagnosed as a familial form of DCM. Recently, more than 630 mutations in 16 different genes have been reported to cause cardiomyopathies. Of these mutations, HCM has been associated with 550 and DCM with more than 52 mutations. In the vast majority of cases these genes encode for sarcomeric contractile proteins: myosin heavy chain (MYH7), myosin binding protein C (MYBPC3), troponin I (TNNT2), troponin T (TNNI3), cardiac α-actin (ACTC) and α-tropomyosin (TPM1). Nearly all of the mutations (86%) are single nucleotide mutations, which can lead to the changes in protein chains. Remaining mutations include small in-frame insertions or deletions and rarely large deletions.

AIM OF THE STUDY

The mutations in both MYH7 and TNNT2 genes represent the majority of currently identifiable disease-causing mutations of hypertrophic and dilated cardiomyopathy. The aim of the study was to analyze both MYH7 and TNNT2 exons in the patients with HCM and DCM diagnosis to improve the diagnostic and genetic consultancy in affected families.

METHODS

Patients

174 unrelated Caucasian patients with HCM (n=84) and DCM (n=90), mean age 48.4 ± 15.1 years, were evaluated in the Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic, and included in this single center study.

Samples

Blood samples were collected via puncture of the cubital vein. Blood samples were stored at -4°C and isolation of DNA was performed by a modified salting out procedure according to Miller et al.

TNNT2 and MYH7 screening

First screening for mutations in TNNT2 gene exons 7 (ITN7N) and 8 (R92W) and MYH7 gene exons 13 (R403L) and 18 (L656S) was performed using restriction fragment length polymorphism (RFLP) analysis. Results were confirmed by DNA sequencing.

TNNT2 sequencing

The entire coding sequences of TNNT2 gene were amplified by PCR. Both strands of purified DNA fragments were then sequenced in CEQ 8000 genetic analysis system (Beckman Coulter, CA, USA) according to the manufacturer's protocol.

RESULTS

The mutations I79N, R92W, R92G, R92L in the TNNT2 gene and mutations R403L, R403Q, R403W, R665S, R665C in the MYH7 gene were screened by RFLP analysis and results were then confirmed by DNA sequencing. Within our study group consisted of 174 patients (84 patients with HCM and 90 patients with DCM), we identified one R629W mutation in exon 8 of the TNNT2 gene in a patient with HCM. We additionally examined all the 15 exons and their flanking regions of the TNNT2 gene in the same group of patients. Using DNA sequence analysis to investigate polymorphisms, small deletions and new mutations, we found genetic variations in exon regions in 55 patients and genetic variations in intron regions in 164 patients (Table 1). We confirmed the presence of a unique mutation R92W (exon 8) in a single HCM patient (Figure 1 and Table 1) and another unique mutation A172S (exon 10) was found in a single DCM patient (Figure 2).

The frequencies of remaining TNNT2 gene polymorphisms from Table 1 correlated with data in the SNP database (dbSNP) of the National Centre for Biotechnology Information (Table 2). No mutations or polymorphisms were identified in the MYH7 gene in HCM or DCM patients.

CONCLUSIONS

The limited genetic screening analysis is not suitable for routine testing of disease-causing mutations in patients with HCM and DCM as only individual mutation-positive cases may be identified. Therefore, this approach cannot be recommended for daily clinical practice even though it currently represents the only available strategy in majority of cardio-centers due to financial reasons. More cost-effective methods enabling wide genome screening are promising and should be implemented in genetic analyses of cardiomyopathies in near future.

Table 1. Genetic variations (mutations, polymorphisms, small deletions) of TNNT2 and MYH7 gene in HCM and DCM patients.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Exon</th>
<th>Position</th>
<th>SNP number</th>
<th>DNA variation</th>
<th>Index of patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNNT2</td>
<td>7</td>
<td>179</td>
<td>c.238G&gt;A</td>
<td>R629W</td>
<td>HCM 95</td>
</tr>
<tr>
<td>MYH7</td>
<td>13</td>
<td>92</td>
<td>c.273G&gt;A</td>
<td>R92W</td>
<td>DCM 64</td>
</tr>
</tbody>
</table>

Figure 1. Genetic screening of the TNNT2 gene (exon 8) by RFLP analysis in the group of patients with HCM.

Figure 2. R92W mutation of the TNNT2 gene was confirmed by DNA sequencing analysis (A). Another mutation A172S was found in exon 10 of the TNNT2 gene in a single patient with DCM (B).

Table 2. TNNT2 gene polymorphisms and small deletions in HCM patients.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Exon</th>
<th>Position</th>
<th>SNP number</th>
<th>DNA variation</th>
<th>Allele frequencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNNT2</td>
<td>7</td>
<td>179</td>
<td>c.238G&gt;A</td>
<td>R629W</td>
<td>0.496 ± 0.054</td>
</tr>
<tr>
<td>MYH7</td>
<td>13</td>
<td>92</td>
<td>c.273G&gt;A</td>
<td>R92W</td>
<td>0.039 ± 0.018</td>
</tr>
</tbody>
</table>

REFERENCES


The study was supported by research project MZO 000097V0005 (0000041485).